基本信息
浏览量:5
职业迁徙
个人简介
Dr. Golub’s research focuses on mechanisms of collagen degradation including bone resorption during periodontal disease (and relevant medical disorders) particularly the role of tissue (“Host”)-derived matrix metalloproteinases, such as the collagenases (e.g., MMP-8) and gelatinases (e.g., MMP-9). In this regard, he was the 1st to develop government (USA, Canada, Europe)-approved MMP-inhibitor drugs for any disease, but particularly for periodontitis and the chronic inflammatory skin disease, rosacea. The same medications have also demonstrated clinical efficacy, and safety, in humans with other inflammatory-collagenolytic diseases such as arthritis, diabetes, cardiovascular disease, and cancer. The 1st generation medications are novel NON-antibiotic regimens of tetracyclines which function, at least in part, by binding calcium & zinc in the catalytic domain of these neutral proteinases. Second-generation medications being developed are bi-phenolic rather than tetra-phenolic, with a similar (even enhanced) cation-binding site, and are derived from novel chemical modifications of the natural spice curcumin. His research includes (but is not limited to) cell and tissue culture, in vivo studies using different animal models, and clinical trials.
研究兴趣
论文共 128 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Drugs and Drug Candidatesno. 4 (2023): 810-826
引用0浏览0引用
0
0
Scientific reportsno. 1 (2023): 15513-14
Frontiers in Dental Medicine (2021)
Journal of inflammation research (2021): 5337-5347
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn